Taken together, these findings imply that a combination of TRPV1 and TRPV2 immunostains may separate low risk (TRPV1+/TRPV2−) and high-risk (TRPV1−/TRPV2+) hepatocellular carcinoma patients. Here, TRPV2 is linked to hepatocellular carcinoma.